Breakthrough trial offers new hope for Tough-to-Treat lung cancer
NCT ID NCT06711900
Summary
This study is testing whether a new drug called SKB264 works better than standard chemotherapy when combined with pembrolizumab immunotherapy for advanced non-small cell lung cancer. It's specifically for patients whose tumors test negative for PD-L1, a marker that often predicts immunotherapy response. The trial will enroll 432 participants to compare how long patients live without their cancer getting worse and monitor side effects of both treatment approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Oriental Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.